ELAN · Elanco Animal Health Inc
Price
Snapshot
50 fields · last close| Market Cap | $11.06B |
| P/E | — |
| Float | 492.8M |
| Beta | 1.75 |
| Volatility | 43.7% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 71.0 |
| Price | 22.14 |
| Change | +0.00% |
| Prev Close | 22.14 |
| Open | 22.04 |
| Day Low | 21.77 |
| Day High | 22.36 |
| Avg Vol | 6 |
| Avg $ Vol | $128.2M |
| 52W High | 27.98 |
| 52W Low | 19.40 |
| 52W Pos | 31.9% |
| From High | −20.87% |
| From Low | +14.12% |
| Max DD 1Y | −26.23% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −2.93% |
| SMA 50 | −6.80% |
| SMA 200 | −6.99% |
| RSI (14) | 39.7 |
| Vol 30D | 25.5% |
| Vol 90D | 39.5% |
| 1Y Range | 19–28 |
| Daily bars | 526 |
| Perf Week | −0.76% |
| Perf Month | −10.29% |
| Perf Quarter | −11.90% |
| Perf Half Y | −4.07% |
| Perf Year | +6.44% |
| Perf YTD | −1.69% |
| Prev Day | +0.00% |
| Clavix | B- |
| Debt / Eq | 0.57 |
| Curr Ratio | 2.17 |
| Int Cover | 3.1× |
| FCF Margin | 6.0% |
| Rev Growth | +6.2% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 12 / 14 |
Clavix risk grade
regraded every trading dayELAN grades B-, 71.0 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (58, mixed). 2 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 12 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| ELAN | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.75 | 0.42 |
| Volatilityannualized | 43.7% | 10.6% |
| Max drawdown, past yearworst peak-to-trough fall | −26.2% | — |
| Typical daily movemedian absolute daily change | 1.40% | — |
| Days beyond ±3%of the last 252 sessions | 52 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ELAN | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.75 | 0.42 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ELAN | |
|---|---|
| 1 week | −0.8% |
| 1 month | −10.3% |
| Year to date | −1.7% |
| 1 year | +6.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ELAN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 21 since 22 Jul |
| Average score0 most bearish, 100 most bullish | 72 |
| Bullish · bearisharticles above 60 · below 40 | 21 · 0 |
| Directionarticles whose tone is improving vs worsening | 21 ↑ 0 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| ELAN | |
|---|---|
| Revenue growthyear over year | +6.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openElanco Animal Health CEO Jeff Simmons spoke at a Bank of America healthcare conference in London, outlining the company's growth strategy, new product launches including Quattro and Zenrelia, and plans to reduce the company's debt. The article does not provide specific financial figures or new announcements beyond these topics.
Elanco Animal Health's CEO Jeff Simmons discussed the company's growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses at a Bank of America healthcare conference in London. The article references 10% reported results and highlights products Quattro and Zenrelia, but the full text is truncated.
Traders bought 3,768 call options on Elanco Animal Health on Tuesday, about five times the usual daily volume of 734. The article does not say why the unusual interest occurred.
Elanco says expanding tick and flea season is driving demand for its pest-protection products, supporting stronger base business and share gains. The company confirmed its U.S. Pet Health segment is on track for high-single digit to low double-digit growth in the second half of 2026; the article is cut off before details on pricing gains.
Elanco says its pest-protection products for ticks and fleas are driving stronger sales and overall market share gains as tick and itch seasons expand. The company confirmed its U.S. Pet Health business is on track for high-single digit to low double-digit growth in the second half of 2026.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CORT | Corcept Therapeutics Inc | C | $12.56B | 227.69 | 0.52 | Compare |
| AXSM | Axsome Therapeutics Inc | B | $9.39B | — | 0.81 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | — | $9.01B | — | 0.45 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $15.30B | 16.26 | 0.37 | Compare |
| VTRS | Viatris Inc | B+ | $20.35B | — | 0.90 | Compare |
| MANE | Veradermics Inc | C+ | $4.88B | — | -0.07 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 11.22 | 0.71 | Compare |
| RPRX | Royalty Pharma PLC | A | $32.87B | 40.33 | 0.39 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.